First published 9/28/2026, 9:40:15 AM · Last updated 9/28/2026, 9:40:15 AM

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study

Journal article published 2026-09-01 by AME Publishing Company reporting a single-center retrospective cohort study of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer after gradual progression on first-line osimertinib. The excerpt states study type and topic but provides no results, outcomes, or study location.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study addresses efficacy and safety of a treatment approach for a specific lung cancer patient subgroup.

Sources

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study

Report an issue